ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

Anti-B7-H4 Antibody Drug Conjugate BG-C9074

Its studies are mostly in Carcinoma, Ovarian Epithelial, led by BeOne Medicines.

Furthest: phase 3, since Sep 3, 20262 company-led studies, 2 open or runningNext primary completion: Sep 28, 2027 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
BeOne Medicines22 open or runningphase 3since Sep 3, 2026Jan 23, 2024Sep 28, 2027phase 1 · NCT06233942

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Jan 23, 2024First study: phase 1 study in Advanced Solid TumorFirst studyNCT06233942 · 308 planned · United States, Australia, Brazil and more
  2. Sep 3, 2026Phase 3 study in Carcinoma, Ovarian EpithelialPhase 3 reachedNCT07811271 · 600 planned

Ahead

  1. Sep 28, 2027Primary completion: phase 1 study in Advanced Solid TumorNCT06233942
  2. Nov 30, 2029Primary completion: phase 3 study in Carcinoma, Ovarian EpithelialNCT07811271

TargetBeta

VTCN1 →read by rule
“An antibody-drug conjugate (ADC) composed of a monoclonal antibody directed against the T-cell checkpoint ligand B7-H4 (V-set domain-containing T-cell activation inhibitor 1; VTCN1; B7x; B7S1) ”NCIt, by rule

Other programs on VTCN1

ProgramCompanyFurthest phaseStudies
mocertatug rezetecanGlaxoSmithKlinephase 311
puxitatug samrotecanAstraZenecaphase 32
Anti-B7-H4/Anti-4-1BB Bispecific Antibody ABL103ruleabl-bio-incphase 22
Anti-B7-H4/MMAE ADC LNCB74ruleligachem-biosciences-incphase 11

Studies

All 2 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07811271Carcinoma, Ovarian Epithelial3Not yet recruitingNov 30, 2029600
NCT06233942Advanced Solid Tumor · United States, Australia, Brazil and more1RecruitingSep 28, 2027308

How it is read

Names in the registry

  • “BG-C9074”, 2 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.